Episodes
Thursday Oct 31, 2024
BioMedWire Podcast featuring Annovis Bio Inc. (NYSE: ANVS) CEO Dr. Maria Maccecchini
Thursday Oct 31, 2024
Thursday Oct 31, 2024
IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.
“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”
“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”
“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”
Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Thursday Oct 31, 2024
Thursday Oct 31, 2024
IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.
“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”
“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”
“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”
Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Monday Sep 09, 2024
Monday Sep 09, 2024
The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.
To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.
“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”
Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
Monday Sep 09, 2024
Monday Sep 09, 2024
The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.
To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.
“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”
Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
Tuesday Sep 03, 2024
Tuesday Sep 03, 2024
The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.
To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.
“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”
“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”
“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”
Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
Tuesday Sep 03, 2024
Tuesday Sep 03, 2024
The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.
To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.
“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”
“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”
“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”
Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
Thursday Aug 08, 2024
Thursday Aug 08, 2024
The latest episode features Rob Etherington, President and CEO of Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”
Thursday Aug 08, 2024
Thursday Aug 08, 2024
The latest episode features Rob Etherington, President and CEO of Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”
Thursday Aug 01, 2024
BioMedWire Podcast featuring Annovis Bio Inc. (NYSE: ANVS) CEO Dr. Maria Maccecchini
Thursday Aug 01, 2024
Thursday Aug 01, 2024
The latest BioMedWire podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.
“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”
Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.
Thursday Aug 01, 2024
Thursday Aug 01, 2024
The latest BioMedWire podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.
“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”
Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.
Thursday Jun 20, 2024
Thursday Jun 20, 2024
The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.
To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.
“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”
Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
Friday Sep 03, 2021
Friday Sep 03, 2021
Conservative alt-coin podcast hosts Drew Taylor and Brent Bates recently welcomed guests and the audience to another episode of their wildly popular Wild West Crypto Show. The program took a somber turn to delve into current events in Afghanistan and remember service members and people who’ve given their lives for this country. The hosts split segments normally reserved for guests to discuss how global events will affect the markets, as well as share their takes on some wild times. Bates’ Over the Fence Post segment showcased his personal riled-up experience to encourage others to attend city council meetings. Taylor’s Cowboy Logic segment highlighted the topic of responsibility and the reasons our president needs to step up and take his full share. In addition, the hosts provided their insight on the roots of the USA in a unique comparison to cryptos. “The interesting thing is . . . we were the first fully decentralized government in the world. Every government before the U.S. government was centralized. There was either a centralized theocracy, monarchy or a dictator . . . We were the first to come along . . . and had some very wise men who set up a decentralized country,” Bates said. “And, in fact, cryptocurrency is going back to the roots of being decentralized. . .”
Wednesday Aug 25, 2021
Wednesday Aug 25, 2021
Conservative alt-coin podcast hosts Drew Taylor and Brent Bates recently welcomed guests and the audience to a lively episode of their wildly popular Wild West Crypto Show. The program delved into “another week at the speed of crypto.” “Folks, let me tell you something. If you’re not diversified, out of just cash, out of just the stock market,” Taylor said, shooting straight with some cowboy friendly and common-sense advice to diversify into cryptos, gold, silver and other assets considering all that’s going on with the financial markets, Afghanistan and world events. The show also featured CryptoCurrencyWire’s Jonathan Keim, to discuss the three hottest stories of the week, as well as the Good, the Bad and the Ugly, Brent’s Over the Fencepost and Taylor’s Cowboy Logic segments. A special guest to the program was the hosts’ long-time buddy, Ronnie Moas, to discuss his book, filled with amazing stories of a time he literally walked 10,000 miles around the world with photographs detailing every bit of his journey. “I have just this insatiable appetite to travel. I mean you only live once, and I always knew, from the time I was in high school, that marriage/kids was not for me. I was not cut out for that . . . I did something that most people would never be able to do,” Moas says, discussing his long trek as well as a recent experience of seeing the beauty of Montana for the first time and his earliest travel days. “My first big trip was actually at age 35. I hadn’t traveled that much . . . I went to Thailand, Japan and Hawaii, and I just got hooked.”
Friday Jul 02, 2021
Friday Jul 02, 2021
CryptoCurrencyWire’s Jonathan Keim shared the latest and greatest in the world of cryptocurrencies, as well as special guest Greg Magarshak, the founder of Intercoin, and his team to discuss their project. “Intercoin was started with a vision that any community in the world — churches, yoga studios, also cities and universities — can have their own coin, their own currency,” Magarshak said, responding to Taylor’s question regarding Intercoin and how it is changing the crypto space. Magarshak went on to explain how cities want to assist their communities, i.e., help the homeless with food, security, etc., but discussed the challenges in doing so without their own currency. Describing his first company’s efforts to build apps for communities, now reaching 9 million people in 95 countries, Magarshak indicates that the idea of Intercoin is to build currencies on top of the social networking apps the team has created.
To watch the latest episode, visit https://ccw.fm/541vg
Friday Jun 11, 2021
Friday Jun 11, 2021
CryptoCurrencyWire’s Jonathan Keim’s take on the latest trends in the world of cryptocurrencies. The Look and Learn segment further featured discussion surrounding the 24-hour globalization of crypto. “Crypto is 24/7. Its lights are on all the time,” Bates said, describing the nuances of cryptocurrency trading. “What a lot of people don’t realize is, with crypto, you’re not only your own compliance department … your own bank … your own back operations; you’re your own trading platform. There are a whole lot of things you have to consider before you just go in there and hit sell… before you go in there and hit buy. I think what will happen over time, and we’ve been talking about this for four years, the exchanges are going to start to consolidate. They’re going to start to give better service, more transparency,” he said, describing the projected future as compared to current trading as the wild, wild west.
To watch the latest episode, visit https://ccw.fm/IZnkH
Thursday May 27, 2021
Thursday May 27, 2021
CryptoCurrencyWire’s Jonathan Keim then shined the spotlight on the latest and greatest in the world of cryptocurrencies. Perhaps the most authentically wild part of the show was spent on the hosts’ takes on the recent crazy ride of cryptos. Taylor described cryptos of late as “bucking like bodacious” and asked viewers whether they stayed on for the eight-second ride or ran for the fences. Bates then gave his view, spicing things up like Texas-style barbecue with some cowboy friendly investment advice. “Look, this ain’t my first rodeo,” he said, with a knowing grin followed with some cowboy logic. “Just relax. If you stay in crypto long enough, you’re gonna see this multiple times again… You know, folks, the closest you’ll ever get to being an actual entrepreneur is investing in an early stage startup. You get a little flavor, and, I’m telling you, it’s just a little flavor for those of us who are entrepreneurs that start something. Bootstrapping it out of the garage, or whatever it starts out at… You’re gonna get that ride, and it’s what makes you enjoy it when you get to the bottom line and you make some good money.”
To watch the latest episode, visit https://ccw.fm/3FeGF
Monday May 17, 2021
Monday May 17, 2021
Crypto Currency Wire Communications Director, Jonathan Keim on The Wild West Crypto Show Episode 161 | BTC Taking in the Shorts, BUT Alt Coins are Rising
BroadcastMay 14, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.
The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.
Wednesday May 12, 2021
Wednesday May 12, 2021
CryptoCurrencyWire’s Jonathan Keim shared the latest and greatest happenings in the world of cryptocurrencies. Richard Heart also joined the program to discuss the HEX project. “The government just prints money out of thin air,” Heart said. “The price of everything just shoots up through the roof. We’ve got all-time highs in the stock market, all-time highs in cryptocurrencies, all-time highs in gold. . . All-time highs in everything. . . And, why? Because they keep printing money.” Heart goes on to discuss inflation and explain the nuances of HEX. “In HEX, people are paid to wait. The longer you lock your money, the larger the share of inflation that you get. It took bitcoin ten years to get to 3.89 inflation, back when it was at $20,000. We just jumped right to that after year one, and we said alright, we’re going to have 3.6 now, right after the first year. And who’s going to get that inflation? The people who lock up their money. And, the longer you lock it, the more you get. And that’s a more fair and honest way that monetizes the time value of money that no other cryptocurrency in the world does. And it’s the only thing any price cares about, is that people buy and hold. So, we directly monetize the only thing the price cares about.”
Friday May 07, 2021
Friday May 07, 2021
Crypto Currency Wire Communications Director, Jonathan Keim on The Wild West Crypto Show Episode 158 | Carnomaly Listed on KuCoin
Broadcast Apr 23, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.
The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.
Friday Apr 30, 2021
Friday Apr 30, 2021
Conservative alt-coin podcast hosts Drew Taylor and Brent Bates recently welcomed guests and the audience to a lively episode of their wildly popular Wild West Crypto Show. The program featured CryptoCurrencyWire’s Jonathan Keim, in a segment appropriately deemed as “Keim Time,” to highlight the latest and greatest happenings in the world of cryptocurrencies. Kristin Boggiano, the president of CrossTower Exchange, also joined the program to discuss the unique features and nuances of CrossTower as compared to other exchanges. With a strong history in finance, Kristin is now able view what’s happening in the digital assets space from a product-creation angle. She focuses on creation of products that enable sophisticated investors the ability to potentially access through a method that’s more traditional. She also looks at various technological developments that help do define how to bring traditional players into the space. “Our product is not just an exchange. We do have spot. We have margin, we’re offering futures and bringing in options,” Kristin said. “But we also have a variety of structured products that we’re introducing to clients as well. In addition, we just hired the former global head of prime finance from Deutsche Bank… He’s been developing our capital markets infrastructure. So, we’re really an infrastructure company in the digital assets space trying to address traditional and emerging technologies.”
To watch the latest episode, visit https://ccw.fm/wUVUk